Neurogene Inc. Quarterly Nonoperating Income (Expense) in USD from Q1 2013 to Q3 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Neurogene Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2013 to Q3 2023.
  • Neurogene Inc. Nonoperating Income (Expense) for the quarter ending September 30, 2023 was $0.000.
  • Neurogene Inc. Nonoperating Income (Expense) for the twelve months ending September 30, 2023 was -$24K, a 36.8% increase year-over-year.
  • Neurogene Inc. annual Nonoperating Income (Expense) for 2022 was -$42K, a 223% decline from 2021.
  • Neurogene Inc. annual Nonoperating Income (Expense) for 2021 was -$13K, a 103% decline from 2020.
  • Neurogene Inc. annual Nonoperating Income (Expense) for 2020 was $451K, a 70.3% decline from 2019.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2023 -$24K $0 +$22K Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 -$46K $0 +$11K Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-10
Q1 2023 -$57K -$14K -$15K -1500% Jan 1, 2023 Mar 31, 2023 10-Q 2023-05-08
Q4 2022 -$42K -$10K -$4K -66.7% Oct 1, 2022 Dec 31, 2022 10-K 2023-03-20
Q3 2022 -$38K -$22K -$22K Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 -$16K -$11K -$6K -120% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-10
Q1 2022 -$10K $1K +$3K Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-08
Q4 2021 -$13K -$6K -$4K -200% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-20
Q3 2021 -$9K $0 -$1K -100% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-14
Q2 2021 -$8K -$5K -$28K -122% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $20K -$2K -$431K -100% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $451K -$2K -$257K -101% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 $708K $1K -$383K -99.7% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-04
Q2 2020 $1.09M $23K -$404K -94.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-05
Q1 2020 $1.5M $429K -$22K -4.88% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-12
Q4 2019 $1.52M $255K -$158K -38.3% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-25
Q3 2019 $1.68M $384K +$180K +88.2% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $1.5M $427K +$199K +87.3% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-12
Q1 2019 $1.3M $451K +$257K +132% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 $1.04M $413K +$149K +56.4% Oct 1, 2018 Dec 31, 2018 10-K 2020-03-12
Q3 2018 $890K $204K -$33K -13.9% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 $923K $228K -$1K -0.44% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-01
Q1 2018 $924K $194K -$12K -5.83% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-07
Q4 2017 $936K $264K Oct 1, 2017 Dec 31, 2017 10-K 2020-03-12
Q3 2017 $237K +$100K +73% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-07
Q2 2017 $229K Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-08
Q1 2017 $206K Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q3 2016 $137K +$255K Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-08
Q4 2015 -$520K -$71K +$202K +74% Oct 1, 2015 Dec 31, 2015 10-K 2018-03-12
Q3 2015 -$722K -$118K -$144K -554% Jul 1, 2015 Sep 30, 2015 10-Q 2015-11-10
Q2 2015 -$578K $42K -$166K -79.8% Apr 1, 2015 Jun 30, 2015 10-Q 2015-08-06
Q1 2015 -$412K -$373K +$1.24M +76.9% Jan 1, 2015 Mar 31, 2015 10-Q 2015-05-12
Q4 2014 -$1.65M -$273K -$78.5K -40.4% Oct 1, 2014 Dec 31, 2014 10-K 2017-03-09
Q3 2014 -$1.57M $26K -$18.5K -41.6% Jul 1, 2014 Sep 30, 2014 10-Q 2015-11-10
Q2 2014 -$1.55M $208K -$597K -74.2% Apr 1, 2014 Jun 30, 2014 10-Q 2015-08-06
Q1 2014 -$958K -$1.61M -$1.6M -11906% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-12
Q4 2013 $642K -$194K Oct 1, 2013 Dec 31, 2013 10-K 2016-03-14
Q3 2013 $44.5K Jul 1, 2013 Sep 30, 2013 10-Q 2014-11-04
Q2 2013 $805K Apr 1, 2013 Jun 30, 2013 10-Q 2014-08-11
Q1 2013 -$13.4K Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-13
* An asterisk sign (*) next to the value indicates that the value is likely invalid.